Author:
Barbet Jacques,Bourgeois Mickaël,Chatal Jean-François
Publisher
Springer Berlin Heidelberg
Reference59 articles.
1. Anderson WT, Strand M (1985) Stability, targeting, and biodistribution of scandium-46- and gallium-67-labeled monoclonal antibody in erythroleukemic mice. Cancer Res 45(5):2154–2158
2. Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R (2009) Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab′)2–a phase I study. J Nucl Med 50(7):1153–1160
3. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE (2002) Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32(2):123–132
4. Apostolidis C, Molinet R, McGinley J, Abbas K, Möllenbeck J, Morgenstern A (2005) Cyclotron production of Ac-225 for targeted alpha therapy. Appl Rad Isot 62(3):383–387
5. Barbet J, Kraeber-Bodéré F, Chatal JF (2008) What can be expected from nuclear medicine tomorrow? Cancer Biother Radiopharm 23(4):483–504